Stockreport

Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment [Yahoo! Finance]

Arvinas, Inc.  (ARVN) 
Last arvinas, inc. earnings: 11/4 05:00 pm Check Earnings Report
PDF data for its investigational PROteolysis TArgeting Chimera/PROTAC B-cell lymphoma 6 protein (BCL6) degrader, called ARV-393, at the European Hematology Association/EHA 2 [Read more]